Please use this identifier to cite or link to this item:
|Title:||A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)|
|Authors:||Burmester, Gerd R.|
Pollak, Daniel Feldman [UNIFESP]
Rangaraj, Madura J.
Mysler, Eduardo F.
Free Univ Berlin
Klinikum Univ Koln
Ctr Hosp Univ Toulouse
Cabrini Med Ctr
Poznan Univ Med Sci
Universidade Federal de São Paulo (UNIFESP)
Arthrit & Diabet Clin Inc
Rheumatol Associates PA
East Penn Rheumatol Associates PC
Hoffmann La Roche Inc
Roche Prod Ltd
Org Med Invest
|Publisher:||Bmj Publishing Group|
|Citation:||Annals of the Rheumatic Diseases. London: Bmj Publishing Group, v. 73, n. 1, p. 69-74, 2014.|
|Abstract:||Objectives This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARD).Methods Patients (n=1262) were randomly assigned to receive tocilizumab-SC 162mg weekly+placebo-IV every 4weeks or tocilizumab-IV 8mg/kg every 4weeks+placebo-SC weekly in combination with traditional DMARD. the primary outcome was to demonstrate the non-inferiority of tocilizumab-SC to tocilizumab-IV with regard to the proportion of patients in each group achieving an American College of Rheumatology (ACR) 20 response at week 24 using a 12% non-inferiority margin (NIM). Secondary outcomes were disease activity score using 28 joints (DAS28), ACR responses, health assessment questionnaire scores and safety assessments.Results At week 24, 69.4% (95% CI 65.5 to 73.2) of tocilizumab-SC-treated patients versus 73.4% (95% CI 69.6 to 77.1) of tocilizumab-IV-treated patients achieved an ACR20 response (weighted difference between groups -4.0%, 95% CI -9.2 to 1.2); the 12% NIM was met. ACR50/70 responses, DAS28 and physical function improvements were comparable between the tocilizumab-SC and tocilizumab-IV groups. the safety profiles of tocilizumab-SC and tocilizumab-IV were similar, and the most common adverse event was infection. Injection-site reactions (ISR) occurred more frequently in the tocilizumab-SC group than in the tocilizumab-IV (placebo-SC) group. No anaphylaxis was reported over the 24weeks.Conclusions Tocilizumab-SC 162mg weekly demonstrated comparable efficacy to tocilizumab-IV 8mg/kg. the safety profile of tocilizumab-SC is consistent with the known and well-established safety profile of tocilizumab-IV, with the exception of a higher incidence of ISR, which were more common with tocilizumab-SC administration.|
|Appears in Collections:||Em verificação - Geral|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.